The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Despite President Donald Trump’s threat last week that tariffs on pharmaceuticals will come “very shortly,” the biopharma ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

The boss of US pharmaceutical giant Eli Lilly has told the BBC there is no looking back from Donald Trump's decision to ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Trump said he would announce pharmaceutical tariffs, as he increased tariffs on China to 125% and paused tariffs for 75 ...